`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ETON PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`EXELA PHARMA SCIENCES, LLC,
`Patent Owner.
`
`
`
`
`
`
`
`
`
`
`
`
`Case PGR2020-00086
`Patent 10,653,719
`
`
`
`
`
`
`
`
`
`
`
`
`PATENT OWNER EXELA PHARMA SCIENCES, LLC’S
`MANDATORY NOTICES
`
`
`
`Case PGR2020-00086
`Attorney Docket No: 48751-0009PS1
`
`
`
`
`
`PATENT OWNER’S MANDATORY NOTICES
`UNDER 37 C.F.R. § 42.8
`
`Pursuant to 37 C.F.R. § 42.8, Patent Owner, Exela Pharma Sciences, LLC
`
`(“Patent Owner”), hereby submits the following Mandatory Notices in response to
`
`the Petition for Post Grant Review of U.S. Patent No. 10,653,719 (the ’719
`
`patent).
`
`1.
`
`Real Party-In-Interest under 37 CFR § 42.8(b)(1)
`
`Exela Pharma Sciences, LLC is the Patent Owner and the Real Party-In-
`
`Interest in this proceeding.
`
`2.
`
`Related Matters under 37 CFR § 42.8(b)(2)
`
`A. The following judicial or administrative matters may affect or be
`affected by a decision in this proceeding:
`Exela Pharma Sciences, LLC v. Eton Pharms., Inc., Case No. 1:20-cv-
`
`00365-MN (D. Del., filed March 16, 2020) (“District Court Action”).
`
`U.S. Patent 10,653,719 issued from U.S. Patent Application 16/773,563,
`
`which is a continuation of U.S. Patent Application 16/746,028, which is a
`
`continuation of U.S. Patent Application 16/665,702, now U.S. Patent No.
`
`10,583,155, which is the subject of Post Grant Review PGR2020-00068. U.S.
`
`Application 16/665,702 is a continuation of U.S. Application 16/248,460, now
`
`U.S. Patent No. 10,478,453, which is subject of Post Grant Review
`
`PGR2020-00064.
`
`2
`
`
`
`Case PGR2020-00086
`Attorney Docket No: 48751-0009PS1
`The following U.S. patent applications claim priority from the
`’719 patent:
`
`B.
`
`
`
`U.S. Applications
`16/850,726
`16/850,962
`16/850,973
`
`
`
`
`3.
`
`Lead and Back-Up Counsel, under 37 CFR § 42.8(b)(3)
`
`The Patent Owner designates the following lead and back-up counsel:
`
`LEAD COUNSEL
`Dorothy P. Whelan, Reg. No. 33,814
`3200 RBC Plaza
`60 South Sixth Street
`Minneapolis, MN 55402
`Tel:
`(612) 337-2509
`Email: PGR48751-0009PS1@fr.com
`Fax:
`(877) 769-7945
`
`4.
`
`BACK-UP COUNSEL
`Alana Mannige, Reg. No. 71,899
`3200 RBC Plaza
`60 South Sixth Street
`Minneapolis, MN 55402
`Tel:
`(404) 892-5005
`Email:
`PTABInbound@fr.com
`Fax:
`(877) 769-7945
`
`Service Information under 37 CFR § 42.8(b)(4)(i) et seq.
`
`Please address all correspondence and service to both counsel as listed
`
`above. Patent Owner consents to service by email at PGR48751-0009PS1@fr.com
`
`and PTABInbound@fr.com (ref.: Docket No. 48751-0009PS1).
`
`3
`
`
`
`Case PGR2020-00086
`Attorney Docket No: 48751-0009PS1
`Respectfully submitted,
`
`/Dorothy P. Whelan/
`Dorothy P. Whelan
`Reg. No. 33,814
`
`
`
`
`
`
`
`Date: October 5, 2020
`
`
`Customer Number 26191
`Fish & Richardson P.C.
`Telephone: (612) 337-2509
`Facsimile: (877) 769-7945
`
`
`
`
`
`
`
`4
`
`
`
`Case PGR2020-00086
`Attorney Docket No: 48751-0009PS1
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 CFR § 42.6(e), the undersigned certifies that on October 5,
`
`2020, a complete and entire copy of this Patent Owner Exela Pharma Sciences,
`
`LLC’s Mandatory Notices and Power of Attorney were provided via email, to the
`
`Petitioner by serving the email correspondence addresses of record as follows:
`
`Ralph J. Gabric
`Eugene Goryunov
`Judy K. He
`Jeff Wolfson
`Haynes and Boone LLP
`2323 Victory Ave., Suite 700
`Dallas, TX 75219
`
`Email: ralph.gabric.ipr@haynesboone.com
`Email: eugene.goryunov.ipr@haynesboone.com
`Email: judy.he.ipr@haynesboone.com
`Email: jeff.wolfson.ipr@haynesboone.com
`
`
`
`
`
`
`
`/Edward G. Faeth/
`Edward G. Faeth
`Fish & Richardson P.C.
`60 South Sixth Street, Suite 3200
`Minneapolis, MN 55402
`(202) 626-6420
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5
`
`
`
`
`
`
`
`
`
`
`